OKYO Pharma to Present at the Bio International Convention

OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on innovative treatments for ocular conditions, will have its CEO, Dr. Gary S. Jacob, present at the Bio International Convention in Boston, MA from June 16-19, 2025. His presentation, titled "Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain," will highlight the promising developments of OKYO’s lead drug candidate, urcosimod, aimed at addressing neuropathic corneal pain (NCP). This condition, which results in severe ocular discomfort, currently lacks an FDA-approved treatment.

NCP is characterized by debilitating pain and sensitivity in the eyes and face, often arising from nerve damage combined with inflammation. Available treatments are limited and generally applied off-label, underscoring the significance of drug candidates like urcosimod. Urcosimod, previously known as OK-101, is a lipid-conjugated chemerin peptide agonist that targets the ChemR23 receptor present on immune and neural cells in the eye. Its innovative design—featuring a lipid anchor—enhances its retention in the ocular environment, potentially increasing its efficacy in reducing pain and inflammation.

The drug has already demonstrated promising results in preclinical studies and Phase 2 trials for dry eye disease, showing statistically significant outcomes in multiple endpoints. OKYO Pharma is currently advancing urcosimod through a recently completed Phase 2 trial specifically for NCP patients, further asserting its commitment to addressing this significant medical need in ocular health.

Investors and stakeholders interested in the latest developments in biopharmaceuticals are encouraged to follow OKYO as it strives to deliver groundbreaking therapies in the ophthalmic field. More information can be found at www.okyopharma.com.

As OKYO Pharma Limited (NASDAQ: OKYO) prepares for its presentation at the Bio International Convention, investors should consider several factors influencing the company's stock and its prospects. The focus of the presentation will be on urcosimod, OKYO’s lead drug candidate, which represents a significant opportunity in a market currently lacking FDA-approved therapies for neuropathic corneal pain (NCP).

The presentation by Dr. Gary S. Jacob will detail the promising early-stage clinical data of urcosimod, which has shown anti-inflammatory and analgesic effects in treating ocular conditions. The recent success of urcosimod in a Phase 2 trial for dry eye disease, combined with its ongoing evaluations for NCP, positions OKYO favorably within a niche yet critical market for ocular pain management. Given that NCP affects thousands of patients globally, the potential demand for an effective treatment is substantial.

As OKYO continues to advance its clinical trials, particularly the just-completed study involving NCP patients, investors should monitor updates on trial results and their subsequent impact on the company’s valuation. Previous trials have demonstrated statistical significance, which not only builds confidence in urcosimod’s efficacy but also enhances the company’s credibility within the biopharmaceutical sector.

Moreover, upcoming data releases, including any future trial findings, could drive stock volatility and present trading opportunities. Investors may want to take a strategic approach, considering buying on dips, especially in the lead-up to trial announcements.

In summary, OKYO Pharma offers a compelling investment opportunity driven by innovative therapeutic development and strategic clinical advancements. Keeping abreast of the upcoming presentation and subsequent clinical trial results will be key for investors looking to capitalize on potential growth in OKYO’s stock price.